Skip to main content

“JDRF research has transformed lives” Theresa May and Nina Wadia talk type 1 diabetes at JDRF fundraiser

JDRF’s Global Research Ambassador, the Rt Hon Theresa May MP, has shared what inspires her to support Breakthrough T1D UK with fellow Ambassador Nina Wadia OBE at an event to raise money for the type 1 diabetes charity.
Breakthrough T1D profile picture
Kate Gerrard 31 May 2022
Theresa May and Nina Wadia

JDRF Global Research Ambassador Theresa May answered questions from the audience about how she managed her type 1 diabetes while in office.

On diagnosis, research and managing type 1 in office

Diagnosed with type 1 diabetes in 2012 when she was Home Secretary, Mrs May became the first world leader with type 1 when she became Prime Minister in 2016. She has been an Ambassador for JDRF since 2020, raising awareness of the condition and championing JDRF’s global research programme.

Speaking at the event, Mrs May said: “Research is vital, and we both know the wide range of research that JDRF funds and supports. It’s enabling us to improve the lives of people with type 1 right now, and to work towards stopping people from developing type 1 in the future.

“The research that JDRF has done has transformed lives.”

Mrs May then answered questions from the audience about how she managed her type 1 diabetes whilst in office, including how she dealt with hypos during long meetings, travelling and attending State Banquets where she could not carb count in advance.

She said: “Formal state banquets aren’t that difficult because they run to a very rigid timetable, so you know exactly when you’re going to eat. Speaking at a dinner event is much harder because you have no idea how quickly the meal will be served.”

In response, Nina warned her: “Don’t ever go to an Indian wedding!”

Type 1 diabetes technology makes a huge difference

Mrs May also talked about the technology that helps her manage type 1.

“The great thing about technology these days is that you’re not worried about testing now and then, because it’s so easy,” she said.

“I use a FreeStyle Libre, which is transformative. Knowing what your blood glucose level is doing at any one moment is crucial, so having the technology to see it clearly on a phone makes a huge difference.”

Nina Wadia, who was awarded an OBE for her services to charity and entertainment in 2020, has supported JDRF since her son, Aidan, was diagnosed with type 1 in 2017.

In contrast to Mrs May, Nina’s son uses both an Omnipod insulin pump and a Dexcom continuous glucose monitor.

She said: “Aidan said he didn’t want wires, so when we were introduced to the Omnipod I said, ‘I’m getting him one of those.’”

Nina has raised significant funds for JDRF research through appearances on Sitting on a Fortune, Celebrity Catchpoint and Celebrity Pointless.

The event was co-sponsored by Abbott and Insulet, and included a fundraising raffle sponsored by Gem Voyager.

Related news

Read more
Breakthrough T1D
2 March 2026

How could ‘cyborg tissue’ help people with type 1 diabetes?

Researchers funded by Breakthrough T1D in America have used small, electrical implant systems in lab-grown, insulin-producing cells.

Read more
B cell t cell black and white
Research
2 February 2026

What are B cells, and why do they matter in type 1 diabetes? New study highlights the importance of immune cell type

New research suggests that B cells play a major role in damaging protective immune cells called Tregs. Protecting Tregs could help protect insulin-producing cells in the early stages of T1D.

Read more
Image showing mother, daughter and father smiling at the camera.
Research
21 January 2026

UK study finds that childhood screening for type 1 diabetes could prevent thousands of emergencies 

A major UK study has shown that screening children for type 1 diabetes (T1D) can identify the condition in its earliest stages, before symptoms appear, offering families time, choices, and hope.

Read more
A girl with type 1 diabetes after a teplizumab injection
Research
12 January 2026

Teplizumab approved in Europe to delay onset of type 1 diabetes

The European Commission has approved Teizeild, the European brand name for the immunotherapy teplizumab, for use in people with stage 2 type 1 diabetes (T1D). This marks an important step forward in efforts to delay the progression of the condition.